Research programme: plasminogen inhibitor - Bayer HealthCare
Alternative Names: BAYLatest Information Update: 25 Jul 2023
At a glance
- Originator Bayer HealthCare
- Class Small molecules
- Mechanism of Action Plasminogen activator inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Blood coagulation disorders
Most Recent Events
- 25 Jul 2023 Discontinued - Preclinical for Blood coagulation disorders in Germany (PO)
- 28 Oct 2018 No recent reports of development identified for preclinical development in Coagulation-disorders in Germany (PO)
- 30 Sep 2014 Preclinical trials in Coagulation disorders in Germany (PO)